Study of MHB088C for Patients With Advanced Solid Malignant Tumors

NCT07102004 ↗

Phase 1/2 Recruiting 515 enrolled Qilu Pharmaceutical Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase I/II, multicenter, open-label clinical trial with dose escalation/dose expansion/efficacy expansion phases, designed to evaluate the safety/tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of MHB088C in participants with advanced solid tumors

Timeline

Start: 2023-06-20
Primary completion: 2026-07
Completion: 2027-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MHB088C	Monoclonal antibody	—	Intravenous

Indications

No indication recorded.